Vesigenurtacel-L: Phase I/II data

Data from 7 patients with high-risk, non-muscle invasive bladder cancer who have reached the 3-month time point in the open-label arm of the Phase II portion of a U.S. Phase I/II trial showed that once-weekly intradermal injections of HS-410 as monotherapy led to 1 complete response and 6 patients remain recurrence free. HS-410 was well tolerated with no serious adverse events reported. Data were presented at the Phacilitate Immunotherapy World Conference in Washington, D.C. This half, Heat expects to complete enrollment of 25 patients in the open-label arm. ...